LFCR
Fiscal year ends May Quarters are offset from the calendar — Q1 is Jun–Aug

Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, cGMP manufacturing, and aseptic filling of complex formulations and highly viscous sterile injectable pharmaceutical and medical device products. The company produces pharmaceutical-grade, non-animal-sourced hyaluronic acid (HA) using a proprietary fermentation-based process, supplying bulk HA and formulated, filled syringes and vials for ophthalmic and orthopedic applications. Lifecore also develops highly viscous non-HA-based sterile injectable products for various medical uses, including wound care, aesthetic surgery, and drug delivery. Its services include analytical method development, formulation development, process scale-up, stability studies, and production of materials for clinical and commercial studies. The company operates three cGMP facilities equipped with semi-automated Restricted Access Barrier Systems and fully automated aseptic filling lines with isolators. Lifecore serves global biopharmaceutical and biotechnology companies, with a focus on the United States and international markets, and holds regulatory certifications from agencies in Europe, Japan, and Brazil. The company was incorporated in 2007 under the name Landec Corporation, which changed its corporate name to Lifecore Biomedical, Inc. in 2022 to reflect its focus on the CDMO business. Lifecore’s predecessor business commenced in the mid-1960s with a focus on microbial diagnostic devices before developing its HA capabilities in the early 1980s.

Summarised from the company's own disclosures, fiscal year ended Aug 2025

Industry Drug Manufacturers - Specialty & Generic Homepage lifecore.com
Sector Healthcare IR page ir.lifecore.com
Tags
contract development and manufacturing, aseptic filling, hyaluronic acid, sterile injectables, ophthalmic products, orthopedic products, fermentation-based manufacturing, clinical trial supplies, medical devices, formulation development, Lifecore Injectables CDMO, Lifecore Biomedical LLC, Landec Corporation, American Medical Research Inc., DIAGNOSTIC Inc.
Press page —

Metrics

Valuation  
Market cap $ 249.42M
Market cap (USD) $ 249.42M
P/E -5.18
PEG —
P/BV -3.40
P/S 1.94
P/OCF —
P/FCF -18.31
Dividend yield —
Turnover / mcap —
Returns  
ROE -612.1%
ROI -28.6%
ROIC -9.6%
Profit margin -30.0%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 22
Quality score -64.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2002 FY 2001 FY 2000
Revenue 128.867M 128.261M 103.269M 185.786M 544.161M 590.366M 557.559M 524.227M 532.257M 541.099M 539.257M 476.813M 441.708M 317.552M 276.729M — — — — — — 183.155M — 209.55M
Net profit -38.717M 12.013M -99.563M -97.431M -32.665M -38.191M 411K 24.829M 10.59M -11.641M 13.544M 19.145M 22.587M 12.696M 3.92M 7.73M 13.542M 29.189M 8.651M — — -1.487M — -3.998M
Free cash flow -13.621M -18.138M -38.923M -50.625M -8.752M -43.727M -28.714M -13.811M 6.735M -19.083M 8.644M 6.159M 12.353M 16.81M 7.785M 4.859M 13.28M -8.844M 6.119M — — -2.647M -14.53M -330K

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2002 FY 2001 FY 2000
Share price 7.12 5.31 3.78 11.58 10.6 8.69 12.28 13.05 12 10.5 13.95 11.16 14.47 6.52 — — — — — — — — — —
Price performance 12m 0.34 0.41 -0.67 0.09 0.22 -0.29 -0.06 0.09 0.14 -0.25 0.25 -0.23 1.22 — — — — — — — — — — —

Filed figures

Figure May 2016 May 2017 May 2018 May 2019 May 2020 May 2021 May 2022 May 2023 May 2024 May 2025
Balance sheet detail
Trade receivables (USD) 46.4M 47.1M 53.9M 69.6M 76.2M 70M 48.2M 29M 31.2M —
↳ YoY growth +0.5% +1.5% +14.4% +29.1% +9.5% -8.1% -31.2% -39.7% +7.3%
↳ 5y CAGR +16.5% +8.1% +8.4% +9.4% +10.5% +8.6% +0.5% -11.6% -14.8%
Borrowings, current (USD) 8.05M 4.94M 4.94M 9.79M 11.6M 0.00 599,000 580,000 773,000 3.44M
Borrowings, non-current (USD) 46.6M 42.3M 37.4M 87.2M 101M 165M 97.6M 84.3M 101M —
Lease liabilities (USD) — — — — 30.8M 27.5M 15M 11M 9.08M 7.7M
Cash and deposits (USD) 9.89M 5.41M 2.9M 1.08M 360,000 1.3M 1.64M 19.1M 8.46M 8.27M
Intangible assets (USD) 21.4M 22.8M 21.8M 15.3M 12.8M 8.04M 5.5M 4.2M 4.2M 4.2M
Right-of-use assets (USD) — — — 0.00 25.3M 20.8M 8.58M 4.28M 2.44M —
Net debt (borrowings + leases - cash) (USD) 44.8M 41.8M 39.4M 95.9M 143M 191M 112M 76.7M 102M 2.87M
Cash flow detail
Operating cash flow (USD) 21.8M 29.3M 19.8M 16M -17M 15M -24.4M -17.4M -217,000 -206,000
Purchases of property, plant and equipment (USD) -40.9M -22.6M -33.6M -44.7M -26.7M -23.8M -26.2M — -18.4M -13.4M
Change in receivables (cash effect) (USD) 73,000 -336,000 -7.31M -8.86M -6.64M 5.78M -6.14M 10.8M -3.26M -2.26M
Change in inventories (cash effect) (USD) -508,000 855,000 -6.53M -10.9M -12.2M -3.35M -5.96M -14.8M 862,000 7.69M
Change in payables (cash effect) (USD) -4.11M -5.19M 4.97M 19.1M -1.25M -5.98M 9.34M 16M -6.68M -1.67M
Interest paid (cash effect) (USD) -2.02M -2.33M -2.29M -5.61M -10.1M -13.2M -16.9M -31M -2.73M -1.91M
Income taxes paid (cash effect) (USD) -2.63M -2.79M -283,000 1.96M 1.12M 7.68M -441,000 -23,000 -72,000 -46,000
Share-based compensation (USD) 3.47M 3.96M 4.4M 3.56M 2.42M 3.36M 2.61M 3.61M 6.2M 10.2M
Operating cash flow before change in receivables (USD) 21.7M 29.7M 27.1M 24.9M -10.4M 9.24M -18.3M -28.3M 3.52M 2.06M
Free cash flow (OCF - PPE - intangibles) (USD) -19.1M 6.74M -13.8M -28.7M -43.7M -8.75M -50.6M — -18.1M -13.6M
Income detail
Research and development expense (USD) 7.23M 9.47M 12.8M 11.5M 11.1M 10.2M 7.84M 8.74M 8.58M 8.26M
↳ 5y CAGR -4.9% -0.3% +6.6% +9.7% +9.7% +7.2% -3.7% -7.4% -5.6% -5.7%
Total comprehensive income (USD) -11.6M 11M 25.5M -673,000 -41.1M -31.2M -96.7M -99M 12M —
Comprehensive income to owners (USD) -11.6M — 25.5M -673,000 -41.1M -31.2M -96.7M -99M 12M —
Provision for credit losses (USD) — — 46,000 421,000 -284,000 418,000 -14,000 163,000 263,000 658,000
Credit cost ratio (credit losses / average receivables) (%) — — 0.1% 0.7% 0.4% 0.6% 0.0% 0.4% 0.9% —
Reported Aug 1, 2016 Aug 11, 2017 Aug 14, 2020 Aug 14, 2020 Oct 7, 2020 Jul 29, 2021 Sep 14, 2022 Aug 9, 2024 Aug 7, 2025 Aug 7, 2025

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Lifecore Biomedical, Inc. — Other Events Bull 3 Bear 0 M&A

As previously disclosed, on September 27, 2026, Lifecore Biomedical, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Lifecore Inc. (“Parent”) and Hazel Merger Sub, Inc. (“Merger Sub”) providing for the merger of Merger Sub with and into the Company (the “Merger”), with the Company surviving as a wholly owned subsidiary of Parent. The closing of the Merger is conditioned on, among other things, the expiration or early termination of the statutory waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”). On November 4, 2026, the Department of Justice and the Federal Trade Commission granted early termination of the waiting period under the HSR Act effective as of November 4, 2026, satisfying the HSR Act condition to the closing of the Merger. The Merger remains subject to the remaining closing conditions and approvals, including the adoption of the Merger Agreement by Company stockholders at a special meeting.

CHASKA, Minn., November 4, 2026 -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced results for the third quarter and nine months ended September 30, 2026.

CEO Commentary

“During the third quarter, Lifecore secured two new technology transfer projects. One will support process performance qualification (PPQ) batches for a biotech company’s new drug application (NDA) for a new chemical entity, and the other will support a currently marketed product for a large pharmaceutical company. We believe these programs will add to Lifecore’s high-value pipeline, and we expect each to contribute to the company’s long-term revenue growth objectives, beginning in 2027,” said Paul Josephs, president and chief executive officer of Lifecore. “In addition, early in the fourth quarter, we secured three new development-phase programs.

Lifecore Biomedical, Inc. — Other Events Bull 0 Bear 0 Routine

As previously disclosed, on September 27, 2026, Lifecore Biomedical, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Lifecore Inc. and Hazel Merger Sub, Inc. On October 16, 2026, the Board of Directors (the “Board”) of the Company established November 4, 2026, as the record date for a special meeting of stockholders of the Company (the “Special Meeting”) to approve, among other things, the adoption of the Merger Agreement and the approval of the merger contemplated thereby. Stockholders of record of the Company as of the close of business on the record date will be entitled to notice of, and to vote at, the Special Meeting. Additional Information and Where to Find It In accordance with the Merger Agreement, the Company will file a preliminary proxy statement with the Securities and Exchange Commission (“SEC”) in connection with the Special Meeting. The Company also intends to file a definitive proxy statement with the SEC for the Special Meeting.

Prompts

Lifecore Biomedical, Inc. (ticker LFCR), listed in United States.

Company History

Date Change Detail
Dec 2, 2022 Renamed LIFECORE BIOMEDICAL, INC. DE → LIFECORE BIOMEDICAL, INC. \DE\
Nov 16, 2022 Renamed LANDEC CORP CA → LIFECORE BIOMEDICAL, INC. DE
Mar 28, 2014 Renamed LANDEC CORP \CA\ → LANDEC CORP CA
— Predecessor Predecessor Lifecore Biomedical Inc (CIK 28626) filed under its own registration; its figures are on its own company page, not shown here.

ETFs Holding Lifecore Biomedical, Inc.

ETF Weight in ETF Shares Market value As of
AVSC 0.00% 5 $ 32.08 Nov 16, 2026